ABAC Therapeutics organized the Meeting for the constitution of the Antibiotic Discovery Spanish Network (AD-SP)

The Spanish Network for The Discovery of New Antibiotics (AD-SP) has been formally constituted in Barcelona by a group of 23 public and private entities including companies, hospitals and universities. The initiative is supported by the Centre for the Development of Industrial Technology (CDTI). The CDTI is a public corporation under the Ministry of Economy and Competitiveness, which promotes innovation and technological development of Spanish companies in the national and international levels. The purpose of the AD-SP is to promote the collaboration between its members, coordinate the relations with the Administration and assume a representative role in national and international forums.

The meeting has been coordinated by Domingo Gargallo-Viola, and promoted by ABAC Therapeutics, a spin-out company from Grupo Ferrer. ABAC Therapeutics is dedicated to the discovery and development of first-in-class, novel mechanism, pathogen-specific antimicrobial agents to treat multi-drug resistant infections. The initiative was presented by Domingo Gargallo-Viola, CSO of ABAC Therapeutics; Youness Ouahid, director of Discovery and Development at Valoralia R & D; Jordi Vila, Director of Microbiology at the Hospital Clinic de Barcelona; Francisco J. López Hernández, Biomedical Research Institute of Salamanca (IBSAL). University of Salamanca; Rafael Canton, Director of Microbiology at the Hospital Universitario Ramón y Cajal, Madrid; Olga Genilloud, Scientific Director of Fundación MEDINA and Juan Luis Romera, Head of the Health Area of Promotion and Coordination Division, CDTI, Madrid.


During the presentation, the experts described the causes of multidrug resistance and insisted on the risks of the antibiotics abuse both in humans and in animals as well as the globalization of multi-resistant pathogens through intercontinental trade and travel. Placing special emphasis on the need for coordination to discover and develop new antibiotics.

The act ended with the nomination of members that initially, will be part of the managing committee. In the managing committee are represented: industry, hospitals, academia and public administration. The nominated members are:

Jornada de la red de Antibióticos 061  – Domingo Gargallo-Viola
    – Youness Ouahid
    – Albert Palomer
    – Jerónimo Pachon
    – Jordi Vila
    – Juan Luis Romera (CDTI)
    – Lluís Ribas
    – Olga Genilloud
    – Rafael Cantón